secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-08-28T23:59:59+00:00
Accession:  0001645113-25-000032
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

NovoCure terminates LUNAR-4 phase 2 trial for metastatic NSCLC, cites real-world evidence alternative
--------------------------------------------------------------------------------

- Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.
- Decision based on availability of real-world evidence to achieve trial objectives without an interventional clinical study.
- Termination is not related to any safety concerns; no impact on other Novocure studies.
- Trial targeted patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000032/0001645113-25-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000032/nvcr-20250828.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer